Healthcare Stock Investor’s Alert – Mylan N.V.(NASDAQ:MYL)
On Tuesday, Shares of Mylan N.V.(NASDAQ:MYL), gained 0.62% to $41.69. The 52-week range of the share price is from $33.60 – $50.40. The beta value for this stock stands at 1.12 points, while its earnings per share (EPS) was $ 0.92. The company has total market capitalization of $ 22.34B and a total of 0.92 outstanding shares.
Mylan N.V. (NASDAQ, TASE: MYL) today declared the appointment of Daniel M. Gallagher as chief legal officer. He will be joining the company on April 17, 2017.
Gallagher joins Mylan from Patomak Global Partners, a consulting firm providing planned advice, compliance consulting, and litigation and regulatory enforcement services, where he was president. From Nov. 2011 to Oct. 2015, Gallagher served as a commissioner of the U.S. Securities and Exchange Commission (SEC). During his tenure at the SEC, he focused on programs aimed at strengthening the U.S. capital markets and encouraging capital formation. As commissioner, he called for reform on various corporate governance issues, advocated for conducting a comprehensive holistic review of equity market structure issues, and encouraged building the Commission’s fixed income market expertise.
Before being designated commissioner, Gallagher served on the staff of the SEC in several capacities, counting as counsel to both SEC Commissioner Paul Atkins and Chairman Christopher Cox, working on matters involving the Division of Enforcement and the Division of Trading and Markets. Gallagher served as deputy director and co-acting director of the Division of Trading and Markets from 2008 to 2010, where he was on the front lines of the agency’s response to the financial crisis, counting representing the Commission in the Lehman Brothers liquidation.
Mylan CEO Heather Bresch commented, “Dan is an outstanding lawyer with an eminent career in both public service and the private sector. In addition to his keen legal intellect and outstanding reputation, Dan’s extensive experience in regulatory matters, financial markets, and corporate legal affairs and governance will add noteworthy value to our senior leadership team and add further depth to Mylan’s already strong legal organization. We believe that the various transformations underway across the global healthcare industry, most notably in the U.S., in addition to Mylan’s own continued evolution into a global healthcare company, will create noteworthy opportunities for us going forward and Dan will be valuable in assisting us to maximize these opportunities.”
Gallagher commented, “Mylan has enjoyed notable growth during a very short period and has become a global powerhouse in the generic and specialty pharmaceutical industry. I have had the opportunity to get to know the company well over the last couple of years and believe Mylan is entirely positioned in the industry as a result of its clear and persuasive vision and strategy, unmatched global assets, strong culture and unwavering commitment to doing what is right. I am eager to join Mylan’s leadership team at this time in the company’s evolution and am honored to lead the company’s world-class legal organization in support of Mylan’s future success.”
In addition to his tenure in public service, Gallagher spent a number of years in the private sector. Following law school, he joined the Washington, D.C. law firm Wilmer Cutler & Pickering, where he advised clients on broker-dealer regulatory issues and represented clients in SEC and SRO enforcement proceedings. He later returned to Wilmer (now WilmerHale) as a partner following his staff service at the SEC. Gallagher also served as senior vice president and general counsel of Fiserv Securities, Inc., where he was responsible for managing all of the firm’s legal and regulatory matters.
Gallagher received his B.A. in English from Georgetown University and his J.D., magna cum laude, from the Catholic University of America, where he was a member of the Law Review.
Gallagher serves as non-executive director of both the Irish Stock Exchange and Symbiont.io, and is on the advisory board of the Drexel LeBow Center for Corporate Governance.
Technical Analysis:
The average true range of the stock is recorded at 0.91and the relative strength index of the stock stands 52.56. The stock price is going above to its 52-week low with 24.91% and down from its 52-week high with -16.73%.
The stock has shown weekly performance of -1.09% and monthly performance stands at -1.07%. The stock price is trading upbeat from its 200 days moving average with 2.49% and up from 50 days moving average with 3.36%.
Analyst recommendation for this stock stands at 2.10.